Biocorrx, Inc. (OTCMKTS:BICX) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of immuno-inflammatory and rare hematologic conditions. Headquartered in Cambridge, Massachusetts, the company is advancing a diversified pipeline of small molecule and nucleic acid–based candidates designed to modulate key disease pathways by targeting aberrant immune responses.
Since its founding in 2016, Biocorrx has built expertise in proprietary drug delivery platforms aimed at enhancing the bioavailability and specificity of its therapeutic compounds. The company's research efforts are concentrated on lead programs in early- to mid-stage clinical development, addressing chronic autoimmune disorders and complement-mediated hemolytic diseases. In addition to internal R&D, Biocorrx collaborates with academic institutions and industry partners to accelerate discovery and optimize clinical strategies.
Biocorrx operates research and development facilities in the United States and Europe, with active trial sites spanning North America, Western Europe and select regions in Asia. By leveraging an integrated operational model, the company seeks to streamline the translation of novel mechanisms of action from preclinical proof-of-concept through pivotal clinical studies. This geographic footprint allows Biocorrx to access diverse patient populations and engage with multiple regulatory agencies across jurisdictions.
The company is led by a management team and board of directors comprising seasoned professionals with backgrounds at leading pharmaceutical and biotechnology organizations. Through strategic partnerships, sustained R&D investment and a focus on precision-targeted therapies, Biocorrx has positioned itself at the forefront of innovation in immuno-pharmacology. The company's history of technology development and clinical advancement underscores its commitment to addressing unmet medical needs and improving patient outcomes.
AI Generated. May Contain Errors.
